NCT02740933 is a Phase 1 clinical trial of Demeclocycline in Brain Tumor, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT02740933?

NCT02740933 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT02740933?

Interventions in NCT02740933: Demeclocycline.

What condition does NCT02740933 study?

NCT02740933 studies Brain Tumor.

Is NCT02740933 still recruiting?

NCT02740933 is currently status unknown. Last updated 12 April 2016.

Last reviewed 2016-04-12 · How we verify

NCT02740933

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors

Status unknown Phase 1 Last updated 12 April 2016

What this trial tests

Phase 1 trial testing Demeclocycline in Brain Tumor in 40 participants. Status unknown.

Timeline

1 April 2016

Primary endpoint
1 January 2019

1 January 2021

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	1 April 2016
Primary completion	1 January 2019
Estimated completion	1 January 2021
Sites	1 location across United States

Drugs / interventions tested

Demeclocycline (DEMECLOCYCLINE) — full drug profile →

Conditions studied

Brain Tumor — all drugs for Brain Tumor →

Sponsor

Massachusetts General Hospital

Who can join

21 and older, any sex, with Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Detectable fluorescence in brain tumors by confocal microscopy after oral dosing of demeclocycline (Y/N).
Time frame: 2 years
Detectable fluorescence via confocal microscopy

Sponsor's own description

This research study is studying a drug called Demeclocycline that may help brain surgeons see tumors with a microscope during surgery.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Oncologic Procedures Amenable to Fluorescence-guided Surgery.
Tipirneni KE, Warram JM, Moore LS, Prince AC, et al · · 2017 · cited 116× · PMID 28045715 · DOI 10.1097/sla.0000000000002127
Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.
Barth CW, Gibbs SL. · · 2020 · cited 79× · PMID 32255887 · DOI 10.1117/12.2545292
Targeted optical fluorescence imaging: a meta-narrative review and future perspectives.
Schouw HM, Huisman LA, Janssen YF, Slart RHJA, et al · · 2021 · cited 48× · PMID 34633509 · DOI 10.1007/s00259-021-05504-y
Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future.
Sun R, Cuthbert H, Watts C. · · 2021 · cited 28× · PMID 34298721 · DOI 10.3390/cancers13143508
Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents.
Netufo O, Connor K, Shiels LP, Sweeney KJ, et al · · 2022 · cited 14× · PMID 35631376 · DOI 10.3390/ph15050550

Verify or expand the search:

Other trials of Demeclocycline

Trials testing the same drug.

NCT02576652 — Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement · Phase 4 · completed

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02740933 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 12 April 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02740933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing